Taken together, our findings support previous observations that salivary IgA responses dip after the second IM vaccine dose in COVID‐19 recovered subjects, and suggest that repeated mucosal antigen exposures (either mucosal infection or potentially mucosal vaccination) may be required to maintain robust mucosal IgA and antibody‐mediated Fc‐responses.9 This evidence concerns the gene CD79A and COVID-19.